Product Description
Allobarbital (5,5-diallylbarbituric acid) is a medium to long-acting barbiturate. It is under international control according to the UN Convention on Psychotropic Substances (Schedule IV). It is used as a sedative and hypnotic and in combination with acetaminophen and codeine as an analgesic. Allobarbital exerts anticonvulsive activity through GABA-ergic mechanisms. (Sourced from: https://drugs.ncats.io/drug/8NT43GG2HA)
Mechanisms of Action: GABA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Portugal | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06476483 | N/A |
Enrolling by invitation |
Acute Respiratory Distress Syndrome |
2025-01-30 |
|
| H23133 | N/A |
Completed |
Depressive Disorder |
2023-12-18 |
|
| N22.013 METC-LDD | N/A |
Completed |
Tobacco Use Disorder|Smoking Cessation |
2023-04-19 |
|
| 20/112-PCV | N/A |
Unknown status |
Communicable Diseases|Skin Diseases, Infectious |
2022-07-01 |
|
| 2016721LUC3 | N/A |
Completed |
Pediatric Obesity |
2021-12-31 |
|
| CAPICHe Costs to Australian Private Insurance - Coaching Health | N/A |
Completed |
Chronic Obstructive Pulmonary Disease|Liver Failure|Chronic Pain|Pulmonary Heart Disease|Heart Failure, Chronic|Coronary Artery Disease|Low Back Pain |
2012-06-24 |
|
| FIMDM_CVD | N/A |
Completed |
Ischemic Stroke|Peripheral Arterial Disease|Peripheral Vascular Diseases |
2011-11-01 |
|
| NIS-RDK-DUM-2005/1 | N/A |
Completed |
Asthma |
None |